Paris - Delayed Quote EUR

Ipsen S.A. (IPN.PA)

115.10

+3.70

(+3.32%)

As of 9:51 AM GMT+2. Market Open.

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

PARIS, FRANCE, 24 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-care biopharmaceutical company, today presents its sales for the first quarter of 2024. Q1 2024 Q1 2023 % change €m €m ActualCER1Growth platforms2509.7452.012.8%16.2%New medicines345.514.3n/an/aSomatuline®257.8263.2-2.0%-1.3%Other9.512.4-23.8%-20.5%Total Sales822.4741.910.9%13.3% Highlights Total-sales growth of 13.3% at CER1, or 10.9% as reported, driven by the 16.2%1 increase in sales of the growth platforms2

GlobeNewswire 3 hours ago

IPSEF

IPSEY
Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

The deal, which could be worth up to $1.8 billion, is the latest research collaboration involving small molecule drugs that modify RNA.

BioPharma Dive yesterday

IPSEY
Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Ipsen enters into an option agreement to receive exclusive global rights to two candidates pursued under the collaborationFollowing development candidate validation, Ipsen will assume responsibility for further development and commercialization, leveraging existing neuroscience expertise in movement disordersThis promising platform technology created by Skyhawk allows for the exploration of previously undruggable RNA targets with small molecules, expanding the disease target landscape1 PARIS, FR

GlobeNewswire 2 days ago

IPSEF

IPSEY
Ipsen publishes its 2023 Universal Registration Document

Ipsen publishes its 2023 Universal Registration Document PARIS, FRANCE, 17 April 2024 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty biopharmaceutical group, announces that its 2023 Universal Registration Document has been filed with the French Autorité des Marchés Financiers on 17 April 2024 and registered under the number D.24-0288. The document is available on ipsen.com and amf-france.org. Copies will also be available at Ipsen’s headquarters – 65 quai Georges Gorse, 92100 Boulogne-B

GlobeNewswire 6 days ago

IPSEF

IPSEY
Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

Monthly information relative to the total number of voting rights and shares composing the share capital (in accordance with Article L.233-8 II of the French Commercial Code and Article 223-16 of the General Regulation of the Autorité des Marchés Financiers) Market: Euronext Paris ISIN Code: FR 0010259150LEI: 549300M6SGDPB4Z94P11 Date Total number of shares composing the share capital Total number of voting rights (1) 31 March 2024 83,814,526 Gross total* of voting rights: 132,107,179 Net total*

GlobeNewswire 15 days ago

IPSEF

IPSEY
Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen

Marengo Therapeutics, Inc, a clinical-stage biotech company pioneering a new way to activate T cells that target the Vβ chain of the T cell receptor (TCR) and select the right T cell subsets against cancer, today announced that Ipsen (Euronext: IPN; ADR: IPSEY) has nominated the first clinical drug candidate (DC) of two from its multi-year strategic partnership in oncology.

PR Newswire 21 days ago

IPSEF

IPSEY
Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Ipsen secures exclusive global rights for development and commercialization of STRO-003, an antibody-drug conjugate, completing the final stages of pre-clinical developmentSTRO-003 targets ROR1, a clinically validated antibody drug conjugate (ADC) targetSTRO-003 has shown robust monotherapy efficacy and potential for a differentiated safety profile in preclinical development in solid tumors and hematological malignancies1 PARIS, FRANCE; SAN FRANCISCO, U.S., 02 April 2024 - Ipsen (Euronext: IPN;

GlobeNewswire 22 days ago

IPSEF

IPSEY
Ipsen drug approved by FDA for early pancreatic cancer

The clearance of Onivyde for first-line pancreatic adenocarcinoma triggers a $225 million payment to Merrimack, from whom Ipsen bought the drug.

BioPharma Dive 2 months ago

IPSEY
Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

Approval based on Phase III NAPOLI 3 clinical trial in which Onivyde® regimen (NALIRIFOX) demonstrated statistically significant superiority and clinically meaningful improvements in overall survival and progression-free survival versus nab-paclitaxel and gemcitabine 1NAPOLI 3 represents the first positive Phase III trial in first-line metastatic pancreatic adenocarcinoma (mPDAC) to demonstrate superior overall survival versus the currently approved regimen of nab-paclitaxel and gemcitabine1Oniv

GlobeNewswire 2 months ago

IPSEF

IPSEY
Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Total-sales growth in FY 2023 of 6.7% at CER1 (3.4% as reported) included strong sales from the growth platforms2 and good contributions from the new medicines. A core operating margin of 32.0% (IFRS operating margin of 26.1%), based on further enrichment of the pipeline and accelerated R&D investment, mainly from recent acquisitionsFinancial guidance for 20243 comprises total-sales growth4 greater than 6.0% at CER1 and a core operating margin5 around 30% of total sales, including the impact of

GlobeNewswire 2 months ago

IPSEF

IPSEY
Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

Detailed top-line results from Phase III CONTACT-02 trial demonstrated statistically significant progression-free survival benefit for combination of Cabometyx® and atezolizumab in metastatic castration-resistant prostate cancer Four-year extended follow-up data from landmark Phase III CheckMate -9ER trial reinforce sustained long-term efficacy benefits for the combination of Cabometyx® and nivolumab versus sunitinib in advanced renal cell carcinoma PARIS, FRANCE, 22 January 2024 - Ipsen (Eurone

GlobeNewswire 2 months ago

IPSEF

IPSEY
Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

PARIS, FRANCE, 7 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY), a global specialty-driven biopharmaceutical company, today holds its Capital Markets Day in London, U.K. “Ipsen has made significant progress since our strategic roadmap was implemented three years ago and is today in a great spot,” commented David Loew, Chief Executive Officer, Ipsen. “Our business has been transformed, with the focus on Specialty Care now supported by a stronger pipeline and momentum from our growth platforms,

GlobeNewswire 4 months ago

IPSEF

IPSEY
Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

New Drug Application granted priority review with PDUFA date set for June 10, 2024European Medicines Agency (EMA) has also validated the Marketing Authorization Application (MAA) for elafibranor Investigational elafibranor is the first novel second-line treatment for primary biliary cholangitis (PBC) to be filed in E.U. and U.S. in nearly a decade PARIS, FRANCE, 07 December 2023 - Ipsen (Euronext: IPN; ADR: IPSEY) and GENFIT (Nasdaq and Euronext: GNFT) today announced that the U.S. Food and Drug

GlobeNewswire 4 months ago

IPSEF

IPSEY
IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023

Statement of transactions in own shares from November 06 to November 10, 2023BNP PARIBAS Aggregated presentation by day and by market Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code) IPSEN549300M6SGDPB4Z94P1106/11/2023FR0010259150266110.07AQEU IPSEN549300M6SGDPB4Z94P1106/11/2023FR0010259150710110.64CE

GlobeNewswire 5 months ago

IPSEF

IPSEY
Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

ELATIVE® Phase III trial confirms potential for investigational elafibranor as a novel, first-in-class, dual PPAR α,δ agonist for patients with primary biliary cholangitis.Elafibranor demonstrates significant improvements in biomarkers of disease progression versus placebo, including significant treatment benefit with improvement in biochemical response and alkaline phosphatase (ALP) normalization, along with patient-reported outcomes data suggesting a possible improvement in pruritus.Elafibrano

GlobeNewswire 5 months ago

IPSEF

IPSEY
Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Today, Ipsen (Euronext: IPN) (ADR: IPSEY), a global biopharmaceutical company focused on transformative medicines in oncology, rare disease and neuroscience, and Medison Pharma ("Medison"), a global pharma company focused on providing access to highly innovative therapies to patients in international markets, are pleased to announce the Health Canada approval for Bylvay™ (odevixibat) for the treatment of pruritus in patients aged 6 months or older with Progressive Familial Intrahepatic Cholestas

CNW Group 5 months ago

IPSEF

IPSEY
Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

Company Executives Share Vision and Answer Questions at VirtualInvestorConferences.comNEW YORK, Nov. 10, 2023 (GLOBE NEWSWIRE) -- Virtual Investor Conferences, the leading proprietary investor conference series, today announced the presentations from the Deutsche Bank Depositary Receipts Virtual Investor Conference (“dbVIC”) held on November 8th and 9th are now available for online viewing. REGISTER NOW AT: https://bit.ly/3SyFOaq The company presentations will be available 24/7 for 90 days. Nove

GlobeNewswire 5 months ago

EMHLF

EMHXY

ERPNF
IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023

Statement of transactions in own shares from October 30 to November 03, 2023 BNP PARIBAS Aggregated presentation by day and by market Name of issuerIdentification code of issuer (Legal Entity Identifier)Day of transactionIdentification code of financial instrumentAggregated daily volume (in number of shares)Daily weighted average price of the purchased shares *Market (MIC Code) IPSEN549300M6SGDPB4Z94P1130/10/2023FR001025915022111.80AQEU IPSEN549300M6SGDPB4Z94P1130/10/2023FR0010259150240111.70CEU

GlobeNewswire 5 months ago

IPSEF

IPSEY
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

Virtual Investor Conference on November 8th and 9th, 2023NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in Australia, China, France, Germany, Greece, Hong Kong, Netherla

GlobeNewswire 5 months ago

EMHLF

EMHXY

ERPNF
International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023

NEW YORK, Oct. 31, 2023 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Wednesday, November 8 and Thursday, November 9, featuring live webcast presentations from international companies with American Depositary Receipt (ADR) programs in the US. Representatives from participating companies based in Australia, China, France, Germany, Greece, Hong Kong, Netherlands, Philippines and Taiwan will respond to questions dur

GlobeNewswire 5 months ago

EMHLF

EMHXY

ERPNF

Performance Overview

Return	IPN.PA	CAC 40
YTD	+6.67%	+7.58%
1-Year	+9.67%	+7.10%
3-Year	+48.98%	+29.67%

News

Life

Entertainment

Finance

Sports

New on Yahoo

Yahoo Finance

Ipsen S.A. (IPN.PA)

Ipsen delivers strong sales in the first quarter of 2024, driven by growth platforms & new medicines, and confirms its full-year guidance

Ipsen, Skyhawk to develop RNA-targeting pills for rare brain diseases

Ipsen and Skyhawk Therapeutics announce RNA targeting research collaboration in rare neurological diseases

Ipsen publishes its 2023 Universal Registration Document

Ipsen - Monthly information relative to the total number of voting rights and shares composing the share capital

Marengo Therapeutics Announces First Drug Candidate Nomination from Oncology Collaboration with Ipsen

Ipsen and Sutro Biopharma announce exclusive global licensing agreement for an ADC targeting solid tumors

Ipsen drug approved by FDA for early pancreatic cancer

Ipsen’s Onivyde® regimen, a potential new standard-of-care first-line therapy in metastatic pancreatic adenocarcinoma, approved by FDA

Building on solid FY 2023 results, Ipsen anticipates four launches in 2024

Latest Phase III trial data investigating Cabometyx® in combination with immunotherapy to be presented at ASCO GU 2024

Capital Markets Day 2023 - Ipsen outlines next phase of growth & transformation and provides new mid-term outlook

Ipsen confirms U.S. FDA grants priority review for New Drug Application for elafibranor for the treatment of rare cholestatic liver disease, PBC

IPSEN - Buy-back programme - Art 5 of MAR - Week 45 - 2023

Results from Ipsen’s ELATIVE® pivotal Phase III trial of elafibranor in PBC presented as late breaking data at AASLD congress and published in New England Journal of Medicine

Ipsen and Medison Pharma Announce Health Canada Approval of Bylvay™ (odevixibat) for the treatment of pruritus due to Progressive Familial Intrahepatic Cholestasis (PFIC)

Deutsche Bank ADR Investor Conference: Presentations Now Available for Online Viewing

IPSEN - Buy-back programme - Art 5 of MAR - Week 44 - 2023

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on November 8th and 9th, 2023

Performance Overview